Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Other Operating Expenses: 2009-2025

Historic Other Operating Expenses for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $5.8 million.

  • Aytu Biopharma's Other Operating Expenses fell 12.37% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.0 million, marking a year-over-year increase of 26.48%. This contributed to the annual value of $32.9 million for FY2025, which is 27.50% up from last year.
  • As of Q3 2025, Aytu Biopharma's Other Operating Expenses stood at $5.8 million, which was down 58.71% from $14.0 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Other Operating Expenses ranged from a high of $14.4 million in Q4 2022 and a low of -$53.1 million during Q1 2022.
  • Over the past 3 years, Aytu Biopharma's median Other Operating Expenses value was $6.3 million (recorded in 2024), while the average stood at $8.1 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first slumped by 422.75% in 2021, then skyrocketed by 224.98% in 2022.
  • Over the past 5 years, Aytu Biopharma's Other Operating Expenses (Quarterly) stood at -$11.5 million in 2021, then skyrocketed by 224.98% to $14.4 million in 2022, then tumbled by 57.49% to $6.1 million in 2023, then climbed by 0.93% to $6.2 million in 2024, then decreased by 12.37% to $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q3 2025, $14.0 million for Q2 2025, and $6.1 million during Q1 2025.